WIL IT software deal speed up US FDA drug evaluations? Yes says Instem

Regulatory reviewers spend more time managing incoming data than on the drug evaluation process, says Instem which has inked a deal with WIL Research for its nonclinical IT systems.

Preclinical contract research organisation (CRO) WIL has placed an order with IT technology firm Instem for study-related software systems at all its sites worldwide, expanding on an exclusive nonclinical partnership deal struck back in May.
Among the systems WIL has purchased is Instem’s Submit software, used to support the Standard for Exchange of Nonclinical Data (SEND) which is being adopted by the US Food and Drug Administration (FDA) to speed up the development process by providing a vehicle for easier transportation of results of regulatory toxicology studies to regulators.
“FDA reviewers continue to receive mostly paper or electronic paper (PDF) submissions as they evaluate new applications for drugs,” Julie Jones a spokesperson from Instem told Outsourcing-Pharma.com. “They are then manually entering data for further analysis, which is time consuming and inefficient, taking time away from the primary mission of reviewing the content of submissions.”
“Reviewers are actually spending more time manipulating the incoming data than they are on the actual drug evaluation process.”
WIL has also signed up to use Instem’s Provantis trial monitoring tool that allows its toxicology clients to remotely logon to a secure website to view on-going study data.
“Provantis streamlines processes and workflows with straightforward, intuitive functionality for simple and complex studies within GLP or non-GLP environments,” Jones explained.
David Spaight, CEO at WIL Research said: “I’m confident that our expanded technology investment will enrich our research processes, help develop better controls and provide excellent experiences for every one of our clients, while expanding our capabilities for continued growth.”

此博客中的热门博文

What is preclinical testing?

In the process of preclinical testing of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a preclinical research phase followed, before which, as described above, the potential toxicity of the compou

阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati

阅读全文

Shanghai Medicilon Inc.

搜索此博客